## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*  Yeaton Howard                |   |   | 2. Issuer Name and Ticker or Trading Symbol Akers Biosciences, Inc. [AKER]   |  |  |   |  |  | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  |  |  |  |  |
|---|---|---|--|--|--|---|--|--|--|--|--|--|--|
| (Last) (First) (Middle) C/O AKERS BIOSCIENCES, INC., 201 GROVE ROAD |   |   | 3. Date of Earliest Transaction (Month/Day/Year) 03/29/2019  |  |  |   |  |  | X_Officer (give title below) Other (specify below)  CEO, CFO   |  |  |  |  |
| (Street) THOROFARE, NJ 08086  |   |   | 4. If Amendment, Date Original Filed(Month/Day/Year)   |  |  |   |  |  | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person   |  |  |  |  |
| ate)  | (Zip)   | Т   | able I   | - Non  | ı-Deriv  | ative S   | Securities   | Acquii   | red. Dispe   | osed of, or l  | Beneficially (   | Owned  |  |
| Date  | Date<br>(Month/Day/Year)  | 2A. Deemed<br>Execution Date, i   | 3. Transaction   |  | ction 4  | n 4. Securities Acquired  |  | uired of (D)   | d 5. Amount of Securities  |  |  | 6. 7. Ownership of   | 7. Nature<br>of Indirect<br>Beneficial                           |
|   |   | (Month/Day/Year)  |  | ode  | V  | Amoun   | (A) or t (D)   |  | (Instr. 3 a  | nd 4)  |  | \ /  | Ownership<br>(Instr. 4)  |
| 03/2  | 29/2019   |   | 1  | A  | 1  | 15,000  |  |  | 22,500   |  |  | D  |  |
|   | Table II - I  | Derivative Securi   | ies Ac   |  |  |   |  |  | -  | OMB con  | trol number  | r.   |  |
|   | (6  | e.g., puts, calls, w  | arrant   | s, opt   | tions, c   | onvert  | ible secur   | rities)  |  |  | 1  |  |  |
| 2   | Year) Execution Date  | Code  | f Transaction Number of  |  | 6. Date Exercisable<br>and Expiration Date<br>(Month/Day/Year) |   | 7. Title and<br>Amount of<br>Underlying<br>Securities<br>(Instr. 3 and<br>4)   |  | Derivative<br>Security<br>(Instr. 5)   | Derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | Ownersh<br>Form of<br>Derivativ<br>Security:<br>Direct (I<br>or Indire | Beneficia<br>Ownershi<br>(Instr. 4)  |  |
|   |   |   |  |  | Date   |   | Expiration<br>Date   | Title  | Amount<br>or<br>Number   |  |  |  |  |
|   | NCES, INC.  86  ate)  2. Tr Date (Mor)  03/2  ate line for each | (Middle) NCES, INC., 201  86 ate)  2. Transaction Date (Month/Day/Year)  03/29/2019  ate line for each class of secur  Table II - I  (aransaction enth/Day/Year)  3A. Deemed Execution Data any | Akers Bioscies  (Middle) NCES, INC., 201  atel (Zip)  2. Transaction Date (Month/Day/Year)  03/29/2019  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Execution Date, if any calls, we ransaction empty) and the line for each class of securities beneficially of the company | Akers Biosciences,  (Middle) NCES, INC., 201  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Execution Date, if any (Month/Day/Year)  Table II - Derivative Securities Ac (e.g., puts, calls, warrant cansaction Execution Date, if any (Month/Day/Year)  Table II - Derivative Securities Ac (e.g., puts, calls, warrant Code (Instr. 8)  Transaction Of Deriv Securities Deriv | Akers Biosciences, Inc.    St)                                 | Akers Biosciences, Inc. [AKERST)  (Middle) NCES, INC., 201  3. Date of Earliest Transaction (Morth 203/29/2019  4. If Amendment, Date Original File (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Execution Date, if (Month/Day/Year)  (Month/Day/Year)  A | Akers Biosciences, Inc. [AKER]  st) (Middle) NCES, INC., 201  3. Date of Earliest Transaction (Month/Day 03/29/2019  4. If Amendment, Date Original Filed(Month B6 are) (Zip) Table I - Non-Derivative Securities (Month/Day/Year) A 15,000  ate line for each class of securities beneficially owned directly or indirectly or indi | Akers Biosciences, Inc. [AKER]  3. Date of Earliest Transaction (Month/Day/Year)  (Month/Day/Year)  4. If Amendment, Date Original Filed(Month/Day/Year)  4. If Amendment, Date Original Filed(Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Execution Date, if (Month/Day/Year)  (Month/Day/Year)  2. Transaction Execution Date, if (A) or Disposed of (D) (Instr. 8)  Table II - Derivative Securities Acquired, Disposed of, or Ben (e.g., puts, calls, warrants, options, convertible securing any (Month/Day/Year)  3. Transaction Execution Date, if (Instr. 8)  Persons who respor contained in this for the form displays a contained in this form di | Akers Biosciences, Inc. [AKER]  st) (Middle) NCES, INC., 201 3. Date of Earliest Transaction (Month/Day/Year) (03/29/2019  4. If Amendment, Date Original Filed(Month/Day/Year) (A) or Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired (A) or Disposed of, or Beneficially (Instr. 8) (Instr. 3) | Akers Biosciences, Inc. [AKER]    Akers Biosciences, Inc. [AKER]     St)   | Akers Biosciences, Inc. [AKER]    Akers Biosciences, Inc. [AKER]       | Akers Biosciences, Inc. [AKER]  (Check all applic Director X Officer (give title below)  (Akers Biosciences, Inc. [AKER]  (Check all applic Director X Officer (give title below)  (CEO, CFO  (Instr. 3, 4 and 5))  (Check all applic particulation of the collection of indepting person person of the collection of information contained in this form are not required to respond unletted form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number of the form displays a currently valid OMB control number o | Akers Biosciences, Inc. [AKER]    Akers Biosciences, Inc. [AKER] |

|   | Relationships |              |          |       |  |  |
|---|---------------|--------------|----------|-------|--|--|
| Reporting Owner Name / Address  | Director      | 10%<br>Owner | Officer  | Other |  |  |
| Yeaton Howard<br>C/O AKERS BIOSCIENCES, INC.<br>201 GROVE ROAD<br>THOROFARE, NJ 08086 |               |              | CEO, CFO |       |  |  |

## **Signatures**

| /s/ Howard R. Yeaton            | 03/29/2019 |
|---------------------------------|------------|
| **Signature of Reporting Person | Date       |

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.